Cargando…

Long-term effectiveness and safety of non-vitamin K antagonist anticoagulant in real world practice

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUNDS: Novel oral anticoagulants (NOACs) are effective to prevent stroke in patients with atrial fibrillation. Real world long-term data on the efficacy and safety of NOACs compared to warfarin in Asians are lacking. PURPOSE: We aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roh, S Y, Kim, D Y, Yoon, E L, Lee, H, Lee, K N
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	10.5.1 - Oral Anticoagulation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207013/ http://dx.doi.org/10.1093/europace/euad122.204

Ejemplares similares

The effectiveness and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a Belgian nationwide cohort study
por: Grymonprez, M, et al.
Publicado: (2023)

Should we shift warfarin to non-vitamin K antagonist oral anticoagulants for patients with atrial fibrillation staying well on warfarin for years?
por: Chao, T, et al.
Publicado: (2023)

Immune modulating drugs and oral anticoagulation in kidney transplant recipients: comparison of direct oral anticoagulants versus antagonist of vitamin-k. results from a multicenter prospective study
por: Santoro, F, et al.
Publicado: (2023)

Impact of concomitant proton pump inhibitor during oral anticoagulant treatment
por: Lee, K N, et al.
Publicado: (2023)

Optimal anticoagulation intensity with warfarin for the prevention of thromboembolism with minimal bleeding in Asian patients with atrial fibrillation: multi-center, randomized controlled trial
por: Lee, K H, et al.
Publicado: (2023)

Identification of a real-world clinical model associated with atrial fibrillation in a large french primary care database
por: Sabouret, S P F, et al.
Publicado: (2023)

Omitting transesophageal echocardiography before catheter ablation of atrial fibrillation or left sided atrial tachycardia in patients on oral anticoagulation
por: Maslova, V, et al.
Publicado: (2023)

How good is time-in-therapeutic-range defined warfarin treatment compared to standard dose direct oral anticoagulants? Incidence of stroke in atrial fibrillation in a nationwide registry study
por: Lehto, M, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related strokes and mortality
por: Kang, D S, et al.
Publicado: (2023)

Racial differences in atrial fibrillation-related bleeding and mortality
por: Kang, D S, et al.
Publicado: (2023)

Baseline characteristics of edoxaban treatment in routine clinical practice for patients with non-valvular atrial fibrillation in China (ETNA-AF-China)
por: Guo, X Y, et al.
Publicado: (2023)

Implementation of In-Clinic SARS-CoV-2 Vaccination in Advanced Heart Failure, Lung Disease, and Transplant Clinic
por: Mathai, S.K., et al.
Publicado: (2022)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists
por: Visser, Chantal, et al.
Publicado: (2021)

Perioperative Anticoagulation Management in Spine Surgery: Initial Findings From the AO Spine Anticoagulation Global Survey
por: Louie, Philip, et al.
Publicado: (2020)

COVID-19-Associated Coagulopathy: Safety and Efficacy of Prophylactic Anticoagulation Therapy in Hospitalized Adults with COVID-19
por: Chambers, Isaac, et al.
Publicado: (2020)

Gestion du don de sang lors de la pandémie SARS-CoV-2
por: Rekik, Taicr, et al.
Publicado: (2021)

Suivi de la réponse sérologique au virus SARS-CoV-2 chez des professionnels de santé d'un centre de lutte contre le cancer dans un contexte de pandémie de COVID19 (PRO-SERO-COV)
por: Cantarel, C., et al.
Publicado: (2022)

Les inhibiteurs du système rénine-angiotensine et la mortalité par COVID-19 : une cohorte prospective de 1160 patients hypertendus, et revue de littérature
por: Gault, N., et al.
Publicado: (2021)

Employeurs désorientés par la pandémie : les IDEST prennent contact
por: Colinet, Pascale, et al.
Publicado: (2022)

The Impact of Different Prophylactic Anticoagulation Doses on the Outcomes of Patients with COVID-19
por: Jiménez-Soto, Rodolfo, et al.
Publicado: (2020)

Evaluation of Antiplatelet and Anticoagulation Therapy in High-Risk COVID-19 Patients
por: Ashraf, Farah, et al.
Publicado: (2020)

Optimal Anticoagulant Dosing in Patients with COVID-19, a Retrospective Review
por: Carrillo, Alessandra, et al.
Publicado: (2021)

Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants
por: Camm, A John, et al.
Publicado: (2018)

Non-Vitamin K Antagonist Oral Anticoagulants and the Gastrointestinal Bleeding Risk in Real-World Studies
por: Anghel, Larisa, et al.
Publicado: (2020)

Increasing Doses of Anticoagulation Are Associated with Improved Survival in Hospitalized COVID-19 Patients
por: Ionescu, Filip, et al.
Publicado: (2020)

Status and Radiological Safety Issues on 100 MeV Proton Linac of PEFP/KAERI
por: Y.O. Lee (KAERI)
Publicado: (21/0)

Admission Rothman Index, Aspirin, and Intermediate Dose Anticoagulation Effects on Outcomes in COVID-19: A Multi-Site Propensity Matched Analysis
por: Goshua, George, et al.
Publicado: (2020)

Confinement national lors de la crise sanitaire liée au Sars-Cov2 : quels impacts sur l'activité et la mortalité des résections digestives électives ?
por: Challine, A., et al.
Publicado: (2022)

Anticoagulation Management and Outcomes in Covid-19 Patients:a Multi-Center Retrospective Cohort Study
por: Kaur, Jasmeet, et al.
Publicado: (2020)

Clinical Outcomes in Critically-Ill Patients with COVID-19 Treated with Therapeutic Dose of Anticoagulants for Suspected Thromboembolism
por: Naing, Phyu Thin, et al.
Publicado: (2021)

Hospitalisations pour tentative de suicide pendant les premiers mois de la pandémie de COVID-19, étude observationnelle à partir des bases du PMSI-MCO
por: Jolland, F., et al.
Publicado: (2022)

Safety and effectiveness of anticoagulation with non-vitamin K antagonist oral anticoagulants and warfarin in patients on tuberculosis treatment
por: Lee, Hyun-Jung, et al.
Publicado: (2023)

Edoxaban Vs. Low Molecular Weight Heparin As Anticoagulant Therapy in Hospitalized Patients with Atrial Fibrillation and COVID-19 Infection
por: Olivera, Pável E, et al.
Publicado: (2020)

Meta-analysis of real-world evidence comparing non-vitamin K antagonist oral anticoagulants with vitamin K antagonists for the treatment of patients with non-valvular atrial fibrillation
por: Coleman, Craig I., et al.
Publicado: (2019)

Statin use improves the outcomes in patients with atrial fibrillation: A population-based study
por: Huang, J, et al.
Publicado: (2023)

Real-world data emulating randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with venous thromboembolism
por: Yoon, Dongwon, et al.
Publicado: (2023)

Effectiveness and Safety of Off-label Dosing of Non–vitamin K Antagonist Anticoagulant for Atrial Fibrillation in Asian Patients
por: Lee, Kwang-No, et al.
Publicado: (2020)

EURISOL Multi-MW target MAFF configuration. Radiological protection, radiation safety and shielding aspects
por: Romanets, Y, et al.
Publicado: (03/0)

Morphology-Voltage-P-wave-duration (MVP) score to select patients for continuous atrial fibrillation screening to prevent stroke
por: Xing, L Y, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_llm95pheavklmkhhvotk357a33